Tesamorelin (Tesa) – Comprehensive Research Overview (2026)
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid modification that enhances stability. It is FDA-approved (as Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, making it one of the few GHRH analogs with an approved clinical indication. It is widely researched for visceral fat reduction, GH/IGF-1 axis modulation, and metabolic health.
→ View Tesamorelin (for laboratory research use only)
Chemical Structure and Properties
- Structure: Full GHRH (1-44) with trans-3-hexenoic acid modification at the N-terminus
- Molecular Weight: ≈5,136 Da
- Form: Lyophilized powder for subcutaneous injection
- Key Feature: Enhanced stability vs. native GHRH; FDA-approved for a specific indication
Mechanism of Action
Tesamorelin binds to GHRH receptors on pituitary somatotrophs with high affinity:
- Stimulates pulsatile GH release while preserving natural feedback mechanisms.
- Selectively reduces visceral adipose tissue (VAT) via GH/IGF-1 axis activation.
- Improves lipid metabolism and insulin sensitivity in metabolic disease models.
- Longer stability than native GHRH due to the hexenoic acid modification.
Clinical Evidence and Research Findings
Tesamorelin has the most robust clinical evidence of any GHRH analog, with multiple Phase 3 trials demonstrating significant visceral fat reduction, improved lipid profiles, and quality of life in HIV lipodystrophy. Additional research explores its potential in non-HIV metabolic syndrome, NAFLD/MASLD, and cognitive function in aging populations.
→ Interested in researching Tesamorelin? View Product Options
Benefits (Research & Clinical Observations)
- Selective reduction of visceral adipose tissue
- Elevated IGF-1 with preserved natural GH pulsatility
- Improved lipid metabolism (reduced triglycerides)
- Better body composition and metabolic markers
- Potential cognitive and neuroprotective benefits in aging research
Typical Dosing Protocols (Off-Label / Compounded)
- FDA-approved dose: 2 mg subcutaneous once daily (HIV lipodystrophy)
- Off-label protocols: 1–2 mg subcutaneous once daily (typically at bedtime)
- Cycles: 3–6 months; effects on VAT may diminish after discontinuation
- Often used alone due to its full GHRH sequence activity
Safety Profile and Side Effects
Tesamorelin has a well-characterized safety profile from clinical trials.
Common side effects:
- Injection-site reactions (erythema, pruritus)
- Mild water retention or peripheral edema
- Possible transient glucose elevation
- Arthralgia or myalgia at higher doses
Monitoring recommended: IGF-1, fasting glucose, HbA1c, and lipid panel. Contraindicated in active malignancy, pregnancy, or hypersensitivity to GHRH.
Tesamorelin vs Sermorelin vs CJC-1295 – Quick Comparison
| Aspect | Tesamorelin | Sermorelin | CJC-1295 no DAC |
|---|---|---|---|
| Sequence Length | 44 AA (full GHRH) | 29 AA | 29 AA (modified) |
| FDA Status | Approved (HIV lipodystrophy) | Discontinued approval | Not approved |
| Primary Strength | Visceral fat reduction | Anti-aging / GH deficiency | Pulsing / stacking |
| Clinical Data | Extensive (Phase 3) | Moderate | Limited |
| Dosing | Once daily | Once daily or split | 1–3× daily |
FAQ – Frequently Asked Questions
Is Tesamorelin FDA approved? Yes, as Egrifta for HIV-associated lipodystrophy. Off-label use requires physician supervision.
How does Tesamorelin differ from Sermorelin? Tesamorelin uses the full 44-AA GHRH sequence with a stability modification and has stronger clinical evidence, particularly for visceral fat.
Can Tesamorelin be used for general fat loss? Off-label research suggests benefits in metabolic syndrome and NAFLD, but it is not approved for these indications.
How long until results are seen? Visceral fat reductions are typically measurable within 8–12 weeks; IGF-1 rises within days.
Does Tesamorelin suppress natural GH production? No. It stimulates natural pulsatile GH release and preserves feedback mechanisms.
Summary
Tesamorelin is the most clinically validated GHRH analog available, with FDA approval for visceral fat reduction and a growing body of research in metabolic and cognitive health. Its full GHRH sequence and stability modification make it a powerful tool for GH axis research. As with all compounds in this library, off-label use of Tesamorelin should only be considered under qualified medical supervision with appropriate lab monitoring.
For Laboratory Research Use View Tesamorelin →
Disclaimer This overview is strictly educational and based on publicly available scientific literature and regulatory information as of April 2026. It does not constitute medical advice, endorsement, or encouragement of use. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.